ArticlePloS one2025
Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of glycolysis-related protein expression with prognosis in Canine Pulmonary Adenocarcinoma.The Journal of veterinary medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine invasive urothelial carcinoma (iUC) is a fatal malignant neoplasm that closely resembles human muscle-invasive bladder cancer in terms of histopathological features, molecular alterations, and clinical behavior. These similarities suggest that canine iUC represents a valuable spontaneous model for studying human bladder cancer. Tumor microenvironment (TME) plays a crucial role in tumor progression. Tumor-derived lactic acid has been implicated in the suppression of antitumor immunity and the promotion of tumor growth by altering the metabolic status of immune cells within the TME. However, the interaction between tumor metabolism and immune cells in the TME remains unclear in dogs. This study reanalyzed previously reported RNA-seq data to investigate the mechanisms underlying enhanced glycolysis in canine iUC. ERBB2 overexpression was found to induce AKT phosphorylation and increase extracellular lactic acid levels in vitro, activating the ERBB2-AKT-glycolysis axis and upregulating monocarboxylate transporter 4 (MCT4). MCT4 knockdown by RNA interference or pharmacological inhibition with diclofenac reduced lactic acid levels in the culture supernatant. Furthermore, MCT4 expression in canine iUC tissues was positively correlated with infiltrating regulatory T cell (Treg) counts. Functional studies revealed that lactic acid promoted Treg differentiation and suppressed IFN-γ production by effector T cells. These findings indicate that MCT4 mediates lactic acid efflux from glycolytic tumor cells, contributing to the suppression of antitumor immunity. Targeting tumor metabolism through MCT4 inhibition may represent a promising therapeutic strategy for canine iUC. Therefore, insights from the metabolic and immunological landscape of canine iUC may inform the development of translational therapies for both veterinary and human oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.